SCHEMBL3090722

SCHEMBL3090722

NC(=O)c1ccc(N)c(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.50
CA2 P00918 2/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
CA5B Q9Y2D0 1/20 0.45
LCK P06239 1/20 0.44
CSNK2A1 P68400 1/20 0.43
HIPK2 Q9H2X6 1/20 0.43
TSHR P16473 3/20 0.42
APOBEC3A P31941 1/20 0.42
HTT P42858 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1376911 0.84 ALDH1A1 (0.52) CA2CA12CA1CA4CA6
SCHEMBL1008508 0.83 CDC25B (0.55) CA2CA12CA1CA4CA6
SCHEMBL27557037 0.82 PARP1 (0.54) PARP1CA2CA12CA1CA9
SCHEMBL30468765 0.81 PRKCI (0.52) CA2CA12CA1CA4CA6
SCHEMBL842236 0.81 PRKCI (0.52) CA2CA12CA1CA4CA6
SCHEMBL1428434 0.79 ALDH1A1 (0.49) PARP1LCKTSHRSMN1; SMN2ALDH1A1
SCHEMBL8412857 0.79 ALDH1A1 (0.49) PARP1LCKTSHRSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL11876420 0.79 CA12 (0.42) CA2CA12CA1CA4CA6
SCHEMBL1806409 0.78 PARP1 (0.50) PARP1CA2CA1LCKTSHR
SCHEMBL28354753 0.78 PARP1 (0.50) PARP1CA2LCKCSNK2A1HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
CN-101466686-A C-FMS kinase inhibitor JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 CN disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
US-20080241722-A1 Mixed Crystals Comprising C.I. Pigment Red 170 Derivatives SCHMIDT MARTIN ULRICH 2008-10-02 US disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
EP-1658336-B1 MIXED CRYSTALS COMPRISING CI PIGMENT RED 170 DERIVATIVES CLARIANT PRODUKTE DEUTSCHLAND (DE) 2006-11-22 EP disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed
EP-1658336-A1 MIXED CRYSTALS COMPRISING CI PIGMENT RED 170 DERIVATIVES Clariant Produkte (Deutschland) GmbH (DE) 2006-05-24 EP disclosed
WO-2005019346-A1 MIXED CRYSTALS COMPRISING CI PIGMENT RED 170 DERIVATIVES CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2005-03-03 WO disclosed
WO-2003099936-A1 NOVEL DERIVATIVES OF C.I. PIGMENT RED 170 CLARIANT GMBH (DE) 2003-12-04 WO disclosed
EP-0592438-B1 INDOLE DERIVATIVES PFIZER (US) 1997-08-27 EP disclosed
US-5607951-A SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS PFIZER INC (US) 1997-03-04 US disclosed
US-5578612-A Indole derivatives PFIZER INC. (US) 1996-11-26 US disclosed
US-5559246-A PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST PFIZER INC. (US) 1996-09-24 US disclosed
US-5559129-A SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN PFIZER INC (US) 1996-09-24 US disclosed
US-5545644-A SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS PFIZER INC. (US) 1996-08-13 US disclosed
WO-1992006973-A1 INDOLE DERIVATIVES PFIZER INC. (US) 1992-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER PARP1 3927/4885CA2 710/4885CA12 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.